For the first quarter of 2026, 3M is expected to report consensus revenue of $6.15 billion and earnings per share of $2.01, with its current $105.40 share price trading approximately 11% below the average analyst price target of $118.25. Investors are primarily focused on the company’s Organic Local-Currency Sales Growth to evaluate the fundamental health of the business following the Solventum spin-off.
Market sentiment is currently shaped by the management of massive legal liabilities, specifically the PFAS and Combat Arms settlement payment schedules which impact long-term cash flow. While margin expansion from recent restructuring efforts is anticipated, analysts remain cautious regarding industrial demand in key end-markets like electronics and consumer retail.